Insmed Inc Stock Price, News & Analysis

Insmed Incorporated (Nasdaq:INSM) announced participation in three virtual investor conferences in September 2020. Management will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, Morgan Stanley Annual Global Healthcare Conference on September 15, 2020, and the Cantor Virtual Healthcare Conference on September 17, 2020. Each presentation will be streamed live, accessible on the company's investor relations webpage and archived for 30 days. Insmed focuses on treatments for serious rare diseases, including its product ARIKAYCE®.

Insmed announced the publication of final results from the Phase 2 WILLOW study for brensocatib, a treatment for non-cystic fibrosis bronchiectasis (NCFBE), in the New England Journal of Medicine. Findings showed significant improvement in time to first pulmonary exacerbation compared to placebo, with risk reductions of 42% and 38% for two dosages. The treatment was well tolerated, with manageable adverse events. Insmed aims to initiate a Phase 3 program for brensocatib by year-end 2020, highlighting the urgency for therapeutic options in NCFBE.

Insmed Incorporated (Nasdaq: INSM) announced the grant of inducement awards to 12 new employees as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, these awards include options to purchase a total of 84,520 shares at an exercise price of $28.17 per share, which is the closing price on September 1, 2020. The options come with a ten-year term and a four-year vesting schedule, aimed at incentivizing employee retention and commitment to the company.

Insmed Incorporated (Nasdaq: INSM) has granted inducement awards to 11 new employees, in compliance with NASDAQ Listing Rule 5635(c)(4). These awards, approved by the Compensation Committee, consist of options to purchase a total of 76,960 shares of Insmed common stock at an exercise price of $27.15 per share, based on the closing price on August 3, 2020. The options are valid for a ten-year term and will vest over four years, promoting employee retention and commitment to the company.

Insmed reported strong Q2 2020 results, achieving $42.5 million in total revenue, up from $30.0 million in Q2 2019. U.S. sales of ARIKAYCE reached $41.0 million, reflecting growth amidst COVID-19 challenges. The company also reported a net loss of $61.9 million or $0.64 per share, improving from a $66.5 million loss in the prior year. Notably, brensocatib received FDA Breakthrough Therapy Designation, and ARIKAYCE gained a positive opinion from the CHMP for treating NTM lung infections, signaling potential market expansion.

Insmed Incorporated (NASDAQ: INSM) will announce its second quarter 2020 financial results on August 6, 2020. A conference call for investors is scheduled for 8:30 a.m. ET on the same day, aimed at discussing the financial outcomes and offering a business update. Interested parties can join by calling (888) 317-6003 for domestic or (412) 317-6061 for international access, referencing conference ID 9359069. The call will also be available via live webcast on Insmed's official website.

Insmed has received a positive opinion from the CHMP for ARIKAYCE Liposomal 590 mg, aimed at treating non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in adults with limited treatment options. A final decision from the European Commission is expected in the second half of 2020. This recommendation follows promising results from the Phase 3 CONVERT study, showing improved sputum culture conversion rates when ARIKAYCE is used with a multi-drug regimen. If approved, ARIKAYCE would be the first approved therapy for this condition in both Europe and the United States.

Insmed Incorporated (Nasdaq: INSM) announced on July 6, 2020, the granting of inducement awards to 11 new employees. These awards, approved by Insmed's Compensation Committee, consist of options to purchase a total of 66,400 shares of common stock at an exercise price of $29.19 per share, the closing price on the date of grant (July 1, 2020). The options have a ten-year term and a four-year vesting schedule. Insmed is focused on transforming the lives of patients with serious and rare diseases, with ARIKAYCE® as its first commercial product for treating MAC lung disease.

Insmed announced final results from the Phase 2 WILLOW study of brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE). The study met its primary endpoint, showing significant prolongation of time to first pulmonary exacerbation versus placebo (p=0.027 for 10 mg; p=0.044 for 25 mg). Notably, the 10 mg group had a 42% reduction in exacerbation risk. The treatment was well-tolerated, with the most common adverse events being cough and headache. Following these results, Insmed plans to initiate a Phase 3 program for brensocatib in bronchiectasis in the second half of 2020.